Cardiopulmonary Stress Testing Systems Market Proliferates on Back of Growing Incidence of Cardiovascular Diseases Associated Death

Various healthcare organizations claim that cardiovascular disease (CVD) is one of the main causes of death around the globe. In 2015, approximately 17.1 million deaths were caused due to cardiovascular diseases, across the world. Out of all the deaths, around three-quarters of the deaths were reported from middle and low income countries. Sedentary lifestyles and restricted access to monitoring and diagnostic devices are some of the prominent reasons behind rise in number of deaths due to cardiovascular diseases.

Further, outbreak of COVID-19 has complicated the concern. The disease is posing severe threat to patients suffering from the cardiovascular diseases. As per medical researcher, the novel coronavirus is likely to damage cardiac tissue by inflaming them.

In order to bring the condition into control, hospitals and other healthcare facilities have elevated the level of medical care. This may help to regulate the condition in existing patients.

Also, government bodies in collaboration with various regional and international non-profit organizations have initiated campaigns to raise awareness among people regarding assessment of cardiovascular diseases.

Registering the aforementioned factors, the global cardiopulmonary stress testing market is anticipated to witness significant growth rate in the forecast period (2020-2025).

Well Developed Healthcare Infrastructure Drives the Market in North America

In the global cardiopulmonary stress testing market, North America is anticipated to hold one-third of the market. Prominence of the region is attributed to growing hospitalization rates and rising efficiency in diagnostic of cardiovascular diseases are projected to push the market growth. As per estimation provided by market analysts, the North American cardiopulmonary stress testing services market will scale at a CAGR of 4.9% in the forecast period.

Meanwhile, Asia Pacific cardiopulmonary stress testing market is estimated to witness lucrative growth rate in the forecast period (2020-2025). The growth rate is attributed to presence of key players in the market. In addition, rising awareness regarding stress testing is another key factor escalating expansion rate of the market. Registering aforementioned factors, the Asia Pacific market is projected to ramp at CAGR of 5.4 % in coming years. As per market analyst, the regional market will account for one-fourth of the global cardiopulmonary stress testing services market during forecast period.

Incorporation of Latest Technology in Devices Aid to Maintain Competitive Edge in Global Cardiopulmonary Stress Testing Services Market

The global cardiopulmonary stress testing services market is found to be fragmented in nature. In the landscape, top five key players account for less than half of the total market share. Some of the prominent key players in the market are VYAIRE MEDICAL INC., Schiller AG, Hill-Rom Holdings Inc., Koninklijke Philips N.V., and GE Healthcare.
Among all the aforementioned players, Schiller AG is the key player in the global cardiopulmonary stress testing services market. The company has been consistently improvising its product by incorporating new technologies for patient assessment using stress tests.

CARDIOVIT AT-200 EXCELLENCE ERGOSPIRO is one of the leading product produced by the company. The device can perform metabolic tests and pulmonary function tests (PFTs). The diagnostic quality varies between 12 or 16-leade exercise ECG conveniently and accurately on a single device.

Similarly, VYAIRE MEDICAL INC., manufactures Vmax and Vyntus CPX CPET devices. Out of two, Vyntus CPX CPET device is equipped with a digital volume transducer (DVT) flow sensor technology. It provides reliable and an accurate flow and measurement of cardiopulmonary functions.